[Field study on the decrease of lipids using etofibrate].
A field-trial on Etofibrat was performed on 4405 patients suffering from primary and secondary hyperlipoproteinemia. The results were proved statistically. After a 3 to 4 weeks treatment the concentration of cholesterol as well as tryglicerides in the serum decreased significantly. After 6 to 8 weeks treatment the lipid-lowering effect was even stronger. Nearly 90% of the patients investigated gave a positive response to the treatment. Part of the population had undergone a treatment with other lipid-lowering agents before-most likely without sufficient success-in these cases a further lipid-lowering effect due to Etofibrat could be shown. Under-dosage in premedication cannot be excluded. The stratification of the patients in different groups of diagnosis showed a nearly similarity of both blood lipids independent of the diagnosis. This could also be confirmed for the group of patients suffering from diabetes. To prove the lipid-lowering efficacy of Etofibrat a population was withdrawn from treatment. Cholesterol as well as tryglicerides increased significantly during the interval without treatment. During a long-term study both lipid fractions could be kept down without increasing of the daily Etofibrat dose. The tolerance of Etofibrat was stated to be good up to very good. Objectively the measured enzymes SGOT, SGPT and gamma-GT showed a decrease of the means. Subjectively the occurrence of an often intermediate heat sensation and/or rubedo was of relevance. The low daily dose compared with other lipid-lowering agents gives indication for a better pharmacocinetic behaviour of the drug;
[Field study on the decrease of lipids using etofibrate]. A field-trial on Etofibrat was performed on 4405 patients suffering from primary and secondary hyperlipoproteinemia. The results were proved statistically. After a 3 to 4 weeks treatment the concentration of cholesterol as well as tryglicerides in the serum decreased significantly. After 6 to 8 weeks treatment the lipid-lowering effect was even stronger. Nearly 90% of the patients investigated gave a positive response to the treatment. Part of the population had undergone a treatment with other lipid-lowering agents before-most likely without sufficient success-in these cases a further lipid-lowering effect due to Etofibrat could be shown. Under-dosage in premedication cannot be excluded. The stratification of the patients in different groups of diagnosis showed a nearly similarity of both blood lipids independent of the diagnosis. This could also be confirmed for the group of patients suffering from diabetes. To prove the lipid-lowering efficacy of Etofibrat a population was withdrawn from treatment. Cholesterol as well as tryglicerides increased significantly during the interval without treatment. During a long-term study both lipid fractions could be kept down without increasing of the daily Etofibrat dose. The tolerance of Etofibrat was stated to be good up to very good. Objectively the measured enzymes SGOT, SGPT and gamma-GT showed a decrease of the means. Subjectively the occurrence of an often intermediate heat sensation and/or rubedo was of relevance. The low daily dose compared with other lipid-lowering agents gives indication for a better pharmacocinetic behaviour of the drug;